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Abstract. Background and aim of the work: Cancer-related fatigue (CRF) is one of the most common symp-
toms experienced by cancer patients (CPs) and negatively affects quality of life. Although CRF is frequently 
experienced, it is often underreported, underdiagnosed and undertreated. The objectives of this study were to 
evaluate the level of fatigue in patients with pancreatic cancer undergoing chemotherapy and to analyse its 
correlation with patients’ demographic and clinical variables. Methods: A cross-sectional observational study 
was implemented in the Oncology Day Hospital of a Northern Italian hospital. A sample of 48 patients re-
ceiving chemotherapy were evaluated through the Brief Fatigue Inventory Italian version (BFI-I) between 1 
May and 12 October 2016. Data were statistically analysed. Results: Most of our patients (94%) experienced 
fatigue. Women as well as patients with an age ≥65 years reported more fatigue. Anemia, pain and a weight 
loss of over 16 kg in the last 6 months were significantly related to the perception of fatigue. Regarding life 
habits, smoking was related to high global score of BFI-I. Conclusions: In accordance with literature, our study 
suggests that fatigue is a frequent symptom influenced by many constitutional, clinical and environmental 
factors. Our results highlight the need for an early and regular evaluation of fatigue among cancer patients, 
in order to implement all those pharmacological and non-pharmacological interventions with proven efficacy 
in attenuating this symptom.
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Background and aim
Pancreatic cancer is the seventh leading cause of 
cancer death (1) and, in 2017, pancreatic cancer deaths 
exceeded breast cancer deaths (2). In the United States, 
approximately 50,000 individuals are diagnosed with 
exocrine pancreatic cancer each year with fatal out-
come for most of them (3). AIOM (Italian Association 
of Medical Oncology) show that 12,500 new cases of 
pancreatic cancer occurred in 2015, which represented 
about 3% of all incident cancers (4). In Italy, pancreatic 
carcinoma is one of the top five causes of cancer death 
in males and the fourth place in females, with greater 
incidence in the North of Italy (5). Pancreatic ductal 
adenocarcinoma has the lowest five-year survival rate 
as compared to others cancers (6).
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In literature there is no univocal definition of 
Cancer-Related Fatigue (CRF), however the most re-
current is that proposed by the National Comprehen-
sive Cancer Network (NCCN) (7), which defines it 
as a persistent distress, a subjective feeling of physical 
exhaustion, related to cancer or to its treatments. The 
fatigue experienced by cancer patients is totally dispro-
portionate in comparison with the physical activity un-
dertaken, highly impacts on the performance of daily 
normal activities, significantly worsening the quality of 
life (7, 8). Fatigue can exacerbate other symptoms and 
negatively influence mood (9). It is different from nor-
mal fatigue since it does not find relief with rest and 
may persist for months or even years after the comple-
tion of chemotherapy treatment (10). CRF has been 
reported as the most common and, for many people, 
the most stressful symptom related to cancer disease 
by the NCCN (7). In accordance with most authors, 
fatigue is one of the most common symptoms related 
to cancer, affecting patients in many domains such as 
physical, emotional, cognitive and behavioral spheres. 
It includes subjective feeling and objective symptoms 
that may persist from the diagnosis of cancer to the 
end of life (11-13). CRF has been hypothesized as the 
result of a complex interaction among multiple factors 
related to both the disease and the side effects of the 
treatments. Nevertheless, it could also be influenced 
by other clinical or environmental factors such as mal-
nutrition, sleep disorders, pain, anxiety and depression 
(14). CRF may be present for a short period or persist 
for years after the end of treatment and therefore it 
can be classified as acute or chronic. In acute fatigue, 
the recovery mechanisms maintain all their effective-
ness, allowing the body to regain its strength and to 
reintegrate the consumed energy through an adequate 
period of rest; in chronic fatigue, the person cannot 
recover an adequate energy level even after prolonged 
rest period and/or suitable supportive therapies (13-
16). The prevalence of fatigue in cancer patients dur-
ing chemotherapy treatment ranges from 25% to 100% 
(11, 17). The different ranges reported in literature can 
be related to the study samples, the treatments received 
and the symptom evaluation methods. It can also be 
influenced by other concomitant pathological condi-
tions, such as anemia and depression, conditions often 
present in patients with various types of cancer (18). 
Patients describe fatigue as a sense of chronic tired-
ness, overwhelming depression, oppressive exhaustion 
and loss of life energy. The terms most commonly used 
to describe this condition are: listlessness, weakness, 
sluggishness, apathy, laziness, abatement, exhaustion, 
etc. (15). Patients are unable to concentrate and often 
present other associated depressive symptoms (19).
In particular, the symptoms of fatigue most com-
monly reported by patients are related to many do-
mains:
•  physical level: impossible to lead a normal life 
and to carry out usual activities; feeling of tired-
ness corresponds to an increased need for sleep 
and rest;
•  psychological level: reduction of motivation and 
interest, feelings of sadness, frustration, irritabil-
ity, loss of the ability to appreciate life and in-
timacy with partner, difficulty in concentrating;
•  social level: loss of interest in relationships with 
friends and colleagues;
•  professional level: difficulty in keeping a job, 
need to change work, request to reduce work 
time (20).
Commonly, fatigue is undertreated although it 
can represent the most debilitating symptoms with 
negative impact on patient and family quality of life 
(15). Recent research on the biological mechanisms 
that underlie CRF has focused on inflammation as a 
key pathway (21). The associations between CRF and 
alterations in the immune and neuroendocrine system 
has been documented. The same association has been 
observed in the Interferon-alpha therapy which pre-
disposes to the development of fatigue (22). In partic-
ular, changes in leukocyte subsets, dysregulated corti-
sol rhythm, reduced glucocorticoid receptor sensitivity, 
and alterations in the autonomic nervous system have 
been correlated with the development of CRF. These 
systems are closely linked to inflammation and may 
influence fatigue by initiating or maintaining elevated 
inflammatory activity (21).
The management of CRF is difficult due to its 
uncertain and complex etiology as well as its subjec-
tive characteristics (23). The guidelines developed by 
the NCCN recommend early treatment of all condi-
tions that may contribute to the onset of fatigue, which 
include pain, emotional disturbances, sleep disorders, 
M. Di Marco, I. Rubbi, A. Baldi, et al.20
anemia, malnutrition, poor physical activity and co-
morbidities for all patients in active treatment, even 
in the long term, and at the end of life. Recommended 
treatments include educational and psychological in-
terventions as well as strategies for fatigue and energy 
management, distraction techniques, pharmacological 
and non-pharmacological interventions (7).
Over the last years, the efficacy of different 
pharmacological approaches has been tested: anti-
depressants, corticosteroids, drugs for anemia and 
psychostimulants (24, 25). Among these drugs, only 
psychostimulants have been shown to improve CRF 
(25). Non-pharmacological interventions have the 
advantage of coping with multiple symptoms without 
inducing any side effect, which makes them particu-
larly acceptable for cancer patients. In the last decade, 
research on the efficacy of non-pharmacological treat-
ments has been increasingly implemented, with par-
ticularly promising results as evidenced by randomized 
controlled trials (RCT) related to the effectiveness of 
physical exercise (26), psycho-educational approaches 
(27) and energy conservation (28). A review of 57 
RCTs that tested the efficacy of non-pharmacological 
interventions concluded that exercise and psycho-so-
cial interventions led to a similar reduction in CRF 
(29).
Although CRF is frequently experienced by can-
cer patients it is often under-recognized by health-care 
professionals and consequently under-treated (9).
Aim
The objective of this study is to evaluate the level 
of fatigue in patients with pancreatic cancer treated in 
an oncology day hospital and to analyze its correlation 
with patients’ demographic variables, clinical condi-
tions, life habits and chemotherapies.
Methods
Study design
To analyze the level of fatigue in patients with 
pancreatic cancer treated with chemotherapy, a cross-
sectional observational study was conducted through 
the administration of a questionnaire, during the pe-
riod between May 1 and October 12, 2016.
Participants
In this study, we included all patients aged 18 
years or over, suffered from a pancreatic cancer and 
treated in the Oncologic Day Hospital of a Northern 
Italian medical center, during the observation period 
of this study, with the following chemotherapy treat-
ments: gemcitabine, gem+abraxane or folfirinox. All 
patients enrolled (n=48) were able to understand the 
questionnaire, to complete it independently and to 
give us their informed written consent for participa-
tion in the study, following our explanation of its pur-
pose and design. 
We excluded patients who were minors, affected 
by other types of cancer, treated with other chemo-
therapies and/or not able to give us their informed 
written consent due to intellectual disability, cognitive 
deterioration or no knowledge of Italian language.
Data were anonymously collected according to 
the current privacy regulations.
Instruments
To evaluate the fatigue level, we administered the 
Brief Fatigue Inventory (BFI), a simple scale validated 
in several languages (30-35), including Italian (BFI-I) 
(36). The validation studies of this instrument showed 
good acceptance by the subjects and good internal 
consistency (30), also in the validation studies of the 
Italian version (Cronbach’s α=0.94) (36).
The BFI is composed of 9 items aimed at assessing 
the severity and impact of fatigue on daily functioning 
in patients with cancer or treatment-related fatigue in 
the previous 24 hours. Three items ask patients to rate 
the severity of their fatigue at the moment of ques-
tionnaire administration at its “usual” and at its “worst” 
level during the previous 24 hrs using a 0-10 Likert 
scale, where 0 corresponds to the description “no fa-
tigue” and 10 with “fatigue as bad as you can imagine”.
Six items focused on how much fatigue had in-
terfered with aspects of the patient’s life during the 
previous 24 hours. Interference items include general 
activity, mood, walking ability, normal work (which in-
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cludes both work outside the home and daily chores), 
relations with other people, and enjoyment of life. 
These items are measured on a 0-10 Likert scale where 
0 means “does not interferes” and 10 “completely in-
terferes”. A global BFI score is calculated as the mean 
of all nine questions, and higher scores correspond to 
more severe fatigue. Patients who could answer at least 
five of the questions were included. The level of fatigue 
can be divided into “mild” (1-3), “moderate” (4-6) and 
“severe” (7-10) in accordance with literature (30, 37-
39).
Statistical analyses
Descriptive statistical analyses were performed: 
means and standard deviations for continuous data, 
and percentages for categorical data, while t-test and 
ANOVA were applied to identify significant differ-
ences among continuous data. Categorical variables 
were calculated through the contingency tables and 
the differences were detected through the Chi-square. 
We analyzed both the total mean score of BIF-I as 
a continuous variable and the four levels of question-
naire score as categorical variables in order to apply 
a sort of sensitivity analysis, in accordance with other 
studies (34, 36, 38). Cronbach’s Alfa allowed us to de-
termine the internal consistency of the questionnaire 
items. The statistical analysis was performed using the 
SPSS software.
Results
Our sample consisted of 48 patients: 29 males 
(60.4%) and 19 females (39.6%). 62.6% of them were 
≥65 years old. The most frequent comorbidity was rep-
resented by cardiovascular diseases (45.8%); smoking 
was the most frequent life habit (22.9%). Most of the 
interviewed patients were treated with gem-abraxane 
(85.4%) (Table 1). 
The internal consistency of the scale was very 
good: Cronbach α=0.905.
We divided the fatigue into four level groups 
according to the BFI-I score: absent (score=0), mild 
(score range=1-3), moderate (score range=4-6) and se-
vere (score range=7-10). 94% of patients experienced 
fatigue according to BFI-I score, mostly mild (n=26) 
and moderate (n=18).
As shown in Table 2, many constitutional and 
clinical variables are statistically significantly cor-
related with the four level groups of fatigue: fe-
males (χ2=8.723, p=.033), patients with age ≥65 years 
(χ2=14.521, p=.024), patients affected by cardiovascular 
comorbid diseases (χ2=62.262, p=<.001), patients with 
smoking habit (χ2=31.077, p=.002) presented statisti-
cally significant higher levels of fatigue. Both mild and 
severe anemia were frequently associated with fatigue 
whereas only a weight decreased from 6 to 15 kg in the 
last 3 months was associated with severe fatigue. The 
other variables selected, chemotherapy drugs, depres-
sion and pain, did not present any statistically signifi-
cant correlation with fatigue (Table 2).
Table 1. Constitutional and clinical variables of our sample
Variables N %
Gender  
Females 19 39.6
Males 29 60.4
Age (years)  
18-50   9 18.7
51-64   9 18.7
≥65 30 62.6
Comorbidities  
Cardiovascular 22 45.8
Endocrine   6 12.5
Neurological   1   2.1
Musculoskeletal   2   4.2
Urogynecological   3   6.3
Infectious   3   6.3
Unknown   7 14.5
No comorbidity   4   8.3
Life habits and correlated disorders  
Smoking 11 22.9
Substance abuse   1   2.1
Eating disorders   5 10.4
Normal 30 62.5
Unknown   1   2.1
Chemotherapies  
Gem-Abraxane 41 85.4
Gemcitabina   6 12.5
Folfirinox   1   2.1
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Table 2. The constitutional and clinical variables correlated with the BFI-I score groups
Variables  Absence Mild Moderate Severe Total Statistical test
 fatigue fatigue fatigue fatigue
 n=3 n=26 n=18 n =1 n=48 Probability
Gender, n (%)
Females -- 7 (26.9) 11 (61.1) 1 (100) 19 (39.6) χ2=8.723
Males 3 (100) 19 (73.1) 7 (38.9) -- 29 (60.4) p=0.033
Age (years), n (%)      
18-50 3 (100) 4 (15.4) 2 (11.1) -- 9 (18.8) χ2=14.521
51-64 -- 5 (19.2) 4 (22.2) -- 9 (18.8) p=0.024
≥65 -- 17 (65.4) 12 (66.7) 1 (100) 30 (62.5) 
Comorbidities, n (%)      
Cardiovascular -- 15 (57.7) 6 (33.3) 1 (100) 22 (45.8) 
Endocrine -- 4 (15.4) 2 (11.1) -- 6 (12.5) 
Neurological -- 1 (3.8) -- -- 1 (2.1) χ2=62.262
Musculoskeletal -- -- 2 (11.1) -- 2 (4.2) p=<0.001
Urogynecological 3 (100) -- -- -- 3 (6.3) 
Infectious -- 1 (3.8) 2 (11.1) -- 3 (6.3) 
Unknown -- -- 4 (22.2) -- 4 (8.3) 
No comorbidity -- 5 (19.2) 2 (11.1) -- 7 (14.6) 
Life habits and correlated disorders, n (%)      
Smoking -- 6 (23.1) 5 (27.8) -- 11 (22.9) 
Substanceabuse -- 1 (3.8) -- -- 1 (2.1) χ2=31.077
Eatingdisorders 3 (100) 2 (7.7) -- -- 5 (10.4) p=0.002
Normal -- 17 (65.4) 12 (66.7) 1 (100) 30 (62.5) 
Unknown -- -- 1 (5.6) -- 1 (2.1) 
Chemotherapies, n (%)      
Gem-Abraxane 3 (100) 20 (76.9) 17 (94.4) 1 (100) 41 (85.4) χ2=3.474
Gemcitabina -- 5 (19.2) 1 (5.6) -- 6 (12.5) p=0.747
Folfirinox -- 1 (3.8) -- -- 1 (2.1) 
Pain, n (%)      
Absent 3 (100) 18 (69.2) 6 (33.3) 1 (100) 28 (58.3) χ2=8.856
Mild -- 7 (26.9) 11 (61.1) -- 18 (37.5) p=0.182
Severe -- 1 (3.8) 1 (5.6) -- 2 (4.2) 
Weight, n (%)      
Unchanged 3 (100) 16 (61.5) 3 (16.7) -- 22 (45.8) 
Increased -- 3 (11.5) 4 (22.2) -- 7 (14.6) χ2=30.374
Decreased from 1 to 15 kg in the previous month -- 1 (3.8) 3 (16.7) -- 4 (8.3) p=0.011
Decreased from 6 to 15 kg in the previous 3 months -- 6 (23.1) 5 (27.8) -- 11 (22.9) 
Decreased by over 16 kg in the previous 6 months -- -- 2 (11.1) 1 (100) 3 (6.3) 
Unknown -- -- 1 (5.6) -- 1 (2.1) 
Anemia, n (%)      
Haemoglobin ≥ 11g/dl 3 (100) 16 (61.5) 5 (27.8) -- 24 (50) χ2=8.940
Haemoglobin 8-10g/dl -- 10 (38.5) 13 (72.2) 1 (100) 24 (50) p=0.030
Depressive disorders, n (%)      
Yes -- 4 (15.4) 2 (11.1) -- 6 (12.5) χ2=2.478
No 3 (100) 22 (84.6) 15 (83.3) 1 (100) 41 (85.4) p=0.871
Unknown -- -- 1 (5.6) -- 1 (2.1)
Evaluating of fatigue in patients with pancreatic cancer receiving chemotherapy treatment 23
The global score of BFI-I showed higher val-
ues among the patients aged from 51 to 64 (M=3.02, 
SD=1.66) and ≥65 (M=2.91, SD=1.92), with a statisti-
cally significant difference between the two genders: 
males had a mean score of 2.18,  SD = 1.66 and females 
one of 3.71, SD=1.78 (t=3.043, p=.004).
As shown in Table 3, the mean scores of BIF-I 
statistically significantly differed among respond-
ents regarding the following variables: comorbidities 
(F=2.782, p=.019), life habits (F=2.98, p=.029), pain 
(F=4.710, p=.014), weight (F=4.419, p=.003) and ane-
mia (F=12.835, p=.001). In particular, the BFI-I scores 
showed high level of fatigue among patients affected 
by musculoskeletal comorbidities (4.2%), smoking 
population (22.9%), patients with mild pain (37.5%), 
patients who decreased weight by over 16 kg in the 
last 6 months (6.3%), patients with Hb values ranged 
between 8-10 g/dL (50% of our sample) (Table 3). 
The impact of fatigue on all daily activities was 
prevalently absent or mild, with severe influence only 
on two dimensions, mood and enjoyment of life, as 
shown in Figure 1. 
Discussion
The findings of our study revealed that 94% of 
our participants experienced CRF during the course of 
Table 3. The constitutional and clinical variables correlated with mean global score of BFI-I 
Variables  BFI-I Confidence Statistical test
 Mean (±SD) interval 95% Probability
Comorbidities   
Cardiovascular 2.66 (1.95) 1.80-3.53 
Endocrine 2.57 (1.22) 1.28-3.85 
Neurological 0.55 (0.0) - F=2.782
Musculoskeletal 5.16 (1.17) -5.42-15.75 p=0.019
Urogynecological 0.07 (0.12) -0.24-0.39 
Infectious 3.81 (1.32) 0.52-7.10 
Unknown 2.77 (1.43) 1.44-4.10 
No comorbidity 4.44 (1.18) 2.55-6.33 
Life habits and correlated disorders   
Smoking 3.29 (1.33) 2.39-4.18 
Substance abuse 3.00 (0.0) - F=2.986
Eating disorders 0.68 (0.95) -0.49-1.86 p=0.029
Normal 2.84 (1.90) 2.12-3.55 
Unknown 6.00 (0.0) - 
Pain   
Absent 2.15 (1.83) 1.44-2.87 F=4.710
Mild 3.75 (1.51) 3.00-4.51 p=0.014
Severe 2.88 (2.04) -15.46-21.24 
Weight   
Unchanged 1.89 (1.44) 1.26-2.53 
Increased 3.04 (2.10) 1.10-4.99 F=4.419
Decreased from 1 to 15 kg in the previous month 3.63 (1.88) 0.64-6.63 p=0.003
Decreased from 6 to 15 kg in the previous 3 months 3.03 (1.45) 2.05-4.00 
Decreased by over 16 kg in the previous 6 months 5.62 (1.50) 1.88-9.37 
Unknown 6.00 (0.0) - 
Anemia   
Haemoglobin ≥11g/dl 1.93 (1.58) 1.26-2.59 F=12.835
Haemoglobin 8-10 g/dl 3.64 (1.73) 2.91-4.38 p=0.001
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treatment. This result is in line with the highest preva-
lence rates of fatigue reported by other studies, which 
ranged CRF between 25 to 100% during the course of 
chemotherapies (11, 17, 39-42). The prevalent consti-
tutional factors associated with fatigue were represent-
ed by female gender and older age, in accordance with 
recent research (17, 42-46). Among clinical variables, 
anemia, loss of weight and pain were associated with 
the highest scores of BFI-I in our study. This result 
overlaps literature and clinical experience concerning 
the close relationship between fatigue and physical 
impairment induced by both cancer and chemothera-
pies. In particular, low hemoglobin levels are associ-
ated with greater fatigue in cancer patients (9, 18, 39, 
40, 42, 47, 48) as well as pain symptoms in accordance 
with most reports (14, 17, 40, 49). Weight loss is a 
significant symptom in this type of cancer, often as-
sociated with neoplastic cachexia. Our analysis shows 
that a weight loss >16 kg in the previous six months is 
related to higher mean score of fatigue. As highlighted 
by other authors, an important weight loss can be con-
sidered a factor that affects the perception of fatigue 
in many patients (50). From our analysis, we can in-
fer that fatigue can be a consequence of both chemo-
therapies and cancer but not of other comorbidities, 
since we found higher levels of fatigue in patients who 
did not have any concomitant disease in comparison 
with others who did. We have to put in evidence that, 
among the comorbidities reported by our patients, the 
ones most correlated with fatigue were cardiovascular 
and musculoskeletal diseases, a result that is in line 
with another study (40). Smoking has also proved to 
be a factor that affects the perception of fatigue: smok-
ing patients reported higher mean score of fatigue 
than non-smokers in our study as in others (17, 51). 
Although the treatment with Gemcitabine+Abraxane, 
to date the elective treatment for metastatic pancreatic 
cancer, has been strongly associated with fatigue as a 
prevalent side effect (52), we did not find any signifi-
cant correlation between this treatment and fatigue.
The BFI-I has shown to be a questionnaire easy to 
administer and simply to answer. The internal consist-
ency of the scale was very good, similar to the value 
obtained in the BFI Italian validation study (36).
Figure 1. The impact of fatigue on daily activities, mood and relationships
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Conclusions
We observe that the majority of our participants 
experienced mild and moderate fatigue. Several fac-
tors influenced the perception of fatigue: gender, pain, 
important weight loss, anemia and smoking. These 
data highlight how fatigue is frequently present as 
a consequence of cancer and its treatments, placing 
importance on CRF diagnosis and recognition to im-
plement early on all those pharmacological and non-
pharmacological interventions with proven efficacy in 
reducing it. 
This study has many limitations, in particular 
its limited sample size, insufficient to draw definitive 
conclusions. Another limitation is represented by the 
period of BFI-I administration from May to October, 
concomitant with the warmest part of the year, which 
can exacerbate the perception of fatigue. In addition, 
other relevant risk factors for fatigue as reported in lit-
erature (41), physical activity, sleep disorders and clini-
cal stage of cancer, were not investigated. 
We can conclude by suggesting that fatigue is a 
multidimensional symptom which can be influenced 
by a variety of constitutional and clinical factors. It 
represents one of the most prevalent and debilitating 
conditions observed in cancer, for which we can sug-
gest a holistic therapeutic approach, based on the ac-
tive involvement of the person in care and treatment 
for fostering clinical recovery with respect for patient 
dignity (53, 54). Education about fatigue should be of-
fered in a tailored way to all patients with cancer, in 
particular to those beginning potential fatigue-induc-
ing treatments (7, 9). Moreover, professionals should 
give their psychological support to patients, reassuring 
them that fatigue can be overcome or reduced con-
comitantly with the treatment implementation. In this 
regard, only an empathic attitude can help profession-
als to better understand the level of fatigue suffered 
from patients  in order to help them to face their fear 
of disease progression.
Further studies focused on fatigue and its multi-
factor aspects are recommended in patients with pan-
creatic cancer who undergo chemotherapy. 
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